655 West Baltimore Street, Bressler Research Building, 8-027
Education and Training
Dr. Mahmood is an Assistant Professor at the Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore. He received his Ph.D. degree in Biochemistry from Hokkaido University, Japan and did his post-doctoral research under a world-famous radiobiologist, Dr. Richard Hill, Dept. of Applied Molecular Oncology, Ontario Cancer Institute (OCI), Princess Margaret Hospital of Toronto University, Canada. Prior to joining at the University of Maryland, he was a Research Associate and Project Lead at the STTARR Innovation Centre, Radiation Medicine Program (RMP), Princess Margaret Hospital of Toronto University, Canada and worked with a world-famous radiation physicist, Dr. David Jaffray. Dr. Mahmood also served as a Lecturer in the Dept. of Cellular Physiology, Faculty of Medicine of Niigata University, Japan and as an Associate Professor at UiTM University, Malaysia.
Dr. Mahmood is currently working as an active team member of the Division of Translational Radiation Sciences (DTRS, UMB) under the leadership of the director, Dr. Zeljko Vujaskovic (MD, Ph.D.) to bring together the department's basic science research activities in radiation biology. Dr. Mahmood`s lab located at the Bressler research building (BRB) of the school of Medicine highly focused on the translational research using Photon and Proton-beam radiation (Maryland Proton Treatment Center) using different tumor xenograft model. Dr. Mahmood is also a graduate faculty in the Molecular Medicine Program of UMB and actively teaching graduate students (MSc, PhD., MD-PhD) and several graduate students are currently working in his lab for their research thesis and lab rotations.
Ph.D. Hokkaido University, Sapporo, Japan, 2001.
Title: Bone regeneration using Bone Morphogenetic Protein (BMP) for tissue engineering (Supervisor: Prof. Yoshinori Kuboki)
Lecturer, Dept of Cellular Physiology, Institute of Nephrology, School of Medicine, Niigata University, Japan 2002-2005.
Postdoctoral Fellow, Applied Molecular Oncology, Radiation Oncology Dept, Princess Margaret Cancer Center, Toronto University, Canada
2006-2010. (Mentors: Professors Richard P Hill)
Visiting Professor, UiTM university, Malaysia, 2011-2012.
Research Associate and Project Lead, STTARR center of Innovation, Princess Margaret Cancer Center, Toronto University, Canada, 2012-2014.
Assistant Professor, University of Maryland School of Medicine, Baltimore, USA 08/2014-present
Lung cancer, Pancreatic Cancer, Prostate Cancer, and Radiation-induced Erectile Dysfunction
Peer-reviewed recent journal articles
a. Kimura M, Zodda A, Mahmood J, Das SK, Nguyen GB, Jackson IL, Vujaskovic Z. Pilot Study Evaluating a Rat Model of Radiation-Induced Erectile Dysfunction Using an Image-Guided Micro-Irradiator. Urology. 2015; 85(5): 1214.e1-6.
b. Shukla HD, Mahmood J, Vujaskovic Z. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer. Cancer Letters. 2015 Dec 1;369(1):28-36.
c. Chun-Rong Wang, Javed Mahmood, Qin-Rong Zhang, Yu-Rui Wu, Ali Vedadi, Robert G. Bristow, David A. Jaffray and Qing-Bin Lu. In Vitro and In Vivo Studies of a New Class of Anticancer Molecules for Targeted Radiotherapy of Cancer. Molecular Cancer Therapeutics. 2016 Apr;15(4):640-50.
d. Mahmood J, Murti SC, Zaveri SR, Shukla HD, Vujaskovic Z. Caveolin-1: A Novel Prognostic Biomarker for Radioresistance in Non-Small Cell Lung Carcinoma (NSCLC) and Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E589-E590.
e. Mahmood J, Sarthak Zaveri, Stephanie Murti, Allen Alexander, Caroline Connors, Hem Shukla & Zeljko Vujaskovic. Caveolin-1: A novel prognostic biomarker of radioresistance in cancer. International Journal of Radiation Biology 2016; VOL. 92, NO. 12, 747–753.
f. Mahmood J, Shamah AA, Creed M, Pavlovic R, Matsui H, Eley J, Jackson I, Vujaskovic Z, Kimura M. Elucidation of the Molecular Mechanism of Radiation-Induced Erectile Dysfunction. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E591.
g. Mahmood J, Shamah A, Creed M, Pavlovic R, Matsui H , Kimura M, Molitoris J, Shukla H, Jackson IL, Vujaskovic Z. Radiation-Induced Erectile Dysfunction: Recent Advances and Future Directions. Advances in Radiation Oncology, 2016: Volume 1, Issue 3, Pages 161–169.
h. Mahmood J, Connors CQ, Alexander AA, Pavlovic R, Samanta S, Soman S, Matsui H, Sopko NA, Bivalacqua TJ, Weinreich D, Ho CY, Eley J, Sawant A, Jackson IL, Vujaskovic Z.Cavernous Nerve Injury by Radiation Therapy May Potentiate Erectile Dysfunction in Rats. Int J Radiat Oncol Biol Phys. 2017 Nov 1;99 (3):680-688.
j. Chuong M, Chang ET, Choi EY, Mahmood J, Lapidus RG, Davila E, Carrier F. Exploring the concept of radiation “booster shot” in combination with an anti-PD-L1 mAb to enhance anti-tumor immune effects in mouse pancreas tumors. Journal of Clinical Oncology and Research (JSM Clin Oncol Res, Aug 2017, 5(2): 1058).
k. Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery. Lamichhane N, Udaykumar TS, D’Souza WD, Simone CB, Raghavan SR, Polf J, and Mahmood J. Molecules (Molecules. 2018 Jan 30;23(2). pii: E288. doi: 10.3390/molecules23020288.).
Dr. Mahmood's research interests are focused on laboratory and translational research studies in tumor and normal tissue radiobiology, metastasis, and aspects of the tumor microenvironment.
- Lung Cancer: Lung cancer is the most commonly diagnosed cancer with the highest mortality rate amongst all cancer in the United States. Radiotherapy is an essential component of the definitive treatment of early-stage and locally-advanced lung cancer, and the palliative treatment of metastatic lung cancer. However, a major obstacle in outcome is the development of radioresistance during treatment. There is an urgent need to find a noninvasive biomarker that can be commonly applied for screening diagnosis, early detection of recurrence, and especially monitoring treatment response of lung cancer patients which is currently unavailable. New emerging technology like proton beam therapy, is a type of radiation treatment that uses protons rather than x-rays to treat cancer. A proton is a positively charged particle. At high energy, protons can destroy cancer cells with minimum side effects to the normal tissues. Dr. Mahmood`s lab is intensively working on detecting a biomarker for radioresistance and photon and Proton beam radiation response for lung cancer using CRISPR technology for cells and patient’s samples from the biorepository.
- Pancreatic cancer: Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of cancer deaths. To achieve long-term success in treating this disease, it is becoming increasingly important to identify effective neoadjuvant/adjuvant multimodal therapies. Local hyperthermia targeting tumor is a promising way to improve cancer treatment in combination with other treatments such as radiation therapy (RT) or chemotherapy. It kills cancer cells by raising the tumor temperature to a “high fever” range (40 and 43°C) which increases blood flow and immune response in the tumor by activating Heat Shock Proteins (HSPs) like HSP70. Furthermore, Immunotherapy has become a major focus of anti-cancer therapy regimens. Patients can have long-lasting anti-tumor immune responses that not only eradicate primary tumors but metastatic lesions as well. Dr. Mahmood`s lab is focusing on a novel triple therapy including combinations of immunotherapies with other treatments that also have effects on the immune system, e.g. radiation therapy (both Photon and Proton beam) or hyperthermia, that could be potentially effective to cure pancreatic cancer.
- Prostate cancer: Prostate cancer (PCa) is second most diagnosed cancer in the United States, with an estimated 180,890 new cases and 26,120 deaths. Radiation therapy (RT) is one of the major treatment modalities administered to PCa patients diagnosed with cancer in the local and regional stages. More than one-half of the prostate cancer patients undergoing RT as a part of their primary treatment develop radiation-induced erectile dysfunction (RiED). The development of RiED is a late side effect of radiation therapy usually demonstrated by patients 3-5 years after treatment completion. Possible loss of sexual function plays an important role in treatment-related decisions for most men diagnosed with prostate cancer. Currently, no specific drug treatment exists to cure RiED. Dr. Mahmood`s lab has developed prostate cancer xenograft model in mice and RiED animal model in rats for testing novel molecules developed by different pharmaceutical companies in a research collaboration to target prostate cancer growth, metastasis and to mitigating RiED of the prostate cancer patients by improving erectile functions.
- Chordoma Research: Chordoma is currently the most common cancer of the sacral and cervical spine. Surgery is the frequently used primary treatment, however, with tumor proximity to vital organs, it can be contraindicated. Despite resection, recurrence rates are high and chordomas tend to be radioresistant. We propose preliminary testing of a novel combination of radiation therapy and hyperthermia in a series of in vitro experiments to show synergistic cancer cell killing in two chordoma cell lines.
Lung cancer, Pancreatic Cancer, Prostate Cancer, and Radiation-induced Erectile Dysfunction (RiED).
- Immunostaining for DNA damage and repair proteins
- General molecular biology including CRISPR technology.
- Colony survival assay.
- BLI imaging of animals.
- Tumor Xenografts in mice.
- Rat surgical model of radiation-induced erectile dysfunction (RiED).
- X-ray radiation to cells and targeted radiation using SARRP radiator with cone beam CT scan.
- Proton beam radiation to cells and animals (MPTC, UMB).